MeSH D015535 - psoriatic arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Apremilast | Apremilast |  | 2022-08-18 |  |  |
| Leflunomide | Repso |  | 2011-03-14 |  |  | |
| Biocon | Adalimumab | Hulio |  | 2020-07-06 |  |  |
| Johnson & Johnson | Infliximab | Remicade |  | 1998-08-24 | $1,653 M | Q2/23-Q1/24 |
| Golimumab | Simponi |  | 2009-10-01 | $2,213 M | Q2/23-Q1/24 | |
| Ustekinumab | Stelara |  | 2009-09-25 | $10,865 M | Q2/23-Q1/24 | |
| Sandoz | Etanercept | Erelzi |  | 2016-08-30 |  |  |
| Adalimumab | Halimatoz |  | 2018-07-26 |  |  | |
| Adalimumab | Hefiya |  | 2018-07-26 |  |  | |
| Adalimumab | Hyrimoz |  | 2018-10-30 |  |  | |
| Infliximab | Zessly |  | 2018-05-18 |  |  | |
| Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-08-25 |  |  |
| AbbVie | Adalimumab | Humira |  | 2002-12-31 | $13,133 M | Q2/23-Q1/24 |
| Risankizumab | Skyrizi |  | 2019-04-26 | $8,411 M | Q2/23-Q1/24 | |
| Novartis | Secukinumab | Cosentyx |  | 2015-01-21 | $4,666 M | Q2/20-Q2/23 |
| Sanofi | Leflunomide | Arava |  | 1999-09-02 |  |  |
| UCB | Certolizumab pegol | Cimzia |  | 2008-04-22 |  |  |
1
2
3
4
5
6
...
8
>
Clinical Trials
Historical Success Rate
Phase 1
62%13/21
Phase 2
63%17/27
Phase 3
90%44/49
Approved: 20Overall Success rate: 35%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use